JEFFERSON CITY — Missouri will get more than $15 million from a national settlement with Abbott Laboratories involving the marketing of the drug Depakote.
Depakote is an anti-seizure and mood-stabilizing drug prescribed for bipolar disorder. The company has admitted marketing the drug for unapproved uses, including treatment of schizophrenia, agitated dementia and autism.
Missouri Attorney General Chris Koster said the improper marketing resulted in false claims to the Medicaid program.
Abbott settled claims from dozens of states this week for more than $1.5 billion.